Ryan Fukushima Sells 41,095 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 41,095 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the transaction, the chief executive officer directly owned 562,463 shares in the company, valued at approximately $27,903,789.43. This represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total value of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The shares were sold at an average price of $46.19, for a total value of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Stock Up 9.1%

Shares of TEM opened at $72.69 on Friday. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The company’s fifty day moving average is $52.93 and its two-hundred day moving average is $51.36. The firm has a market cap of $13.12 billion, a PE ratio of -50.48 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) EPS. Analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Analyst Ratings Changes

TEM has been the topic of several research analyst reports. BTIG Research lifted their price objective on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. TD Cowen restated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Finally, HC Wainwright decreased their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Hold” and an average price target of $65.69.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nykredit A S acquired a new position in shares of Tempus AI during the second quarter worth about $186,000. EMC Capital Management acquired a new stake in shares of Tempus AI in the second quarter valued at about $29,000. Legacy Financial Advisors Inc. purchased a new stake in shares of Tempus AI during the 2nd quarter valued at about $235,000. Headlands Technologies LLC purchased a new stake in shares of Tempus AI during the 2nd quarter valued at about $2,689,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Tempus AI during the 2nd quarter valued at about $1,775,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.